Canakinumab treat-to target strategies increase complete response rate in CAPS
نویسندگان
چکیده
Objective Cryopyrin-associated periodic syndrome (CAPS) is a heterogeneous group of diseases characterized by excessive Interleukin-1b (IL-1 b) release resulting in severe systemic and organ inflammation. Canakinumab targets IL-1b and is approved at standard dose for children and adults with all CAPS phenotypes. Limited data are available regarding real-life effectiveness of canakinumab in patients living with CAPS. Therefore the aim of the study was to evaluate the real-life dosing practice and effectiveness of canakinumab in CAPS.
منابع مشابه
Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
Background CAPS is an orphan auto-inflammatory disease, generally diagnosed in childhood that requires life-long treatment. Canakinumab, a fully human anti-IL-1b antibody, has previously demonstrated rapid, complete and sustained response in CAPS patients. Aim To compare dosing patterns of canakinumab in pediatric and adult CAPS patients of a predominantly Western population (WP) vs Japanese pa...
متن کاملCanakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
INTRODUCTION Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease/chronic infantile neurological cutaneous and articular syndrome (NOMID/CINCA) with etiology linked to mutations in the NLRP3 gene resulting in eleva...
متن کاملCanakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS) patients below 2 years of age: Review of four cases and literature.
Curr Pediatr Res 2017 Volume 21 Issue 4 646 Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different auto-inflammatory hereditary disorders with same genetic basis. CAPS caused mostly due to mutation of NLRP3 gene (nucleotide-binding domain, leucine-rich family (NLR), pyrin domain containing 3), which is an early onset in children. There are many anti-INF agents, anti-IL blocke...
متن کاملIn vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
The investigation of interleukin 1beta (IL-1beta) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti-human IL-1beta antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1beta-antibody complexes allowed the detection of in vivo-produced IL-1beta. A two-compartment mathematical m...
متن کاملA decade of anti-IL-1 therapy in CAPS - a spectrum of efficacy in this spectrum of diseases
Results Patients 1 (male; age at treatment: 40; mutation in NLRP3: T436I; phenotype: CINCA) and 2 (female; 43; R260W; MWS) experienced modest and transient reductions of SAA and symptoms when treated with canakinumab. Both patients developed marked inflammation with morphea-like rash shortly afterwards. Both were switched to anakinra with excellent effect. Patient 3 (male; 47; A439V; FCAS) weig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 13 شماره
صفحات -
تاریخ انتشار 2015